LumiraDx reports Q4, full-year 2021 revenue increases

LabPulse.com staff writers
Mar 13, 2022
2022 03 14 22 03 3798 Graph Arrow Up 400

LumiraDx posted revenue increases for its fourth quarter and full year 2021 (end-December 31).

The company saw full-year 2021 revenues of $421.4 million, up more than 200% from 2020's $139.2 million. Its fourth-quarter revenue was $118.3 million, up 5% from $112.3 million in 2020.

LumiraDx's fourth-quarter 2021 revenues also increased compared to its third quarter ($109.1 million), which the company attributed in part to sales of its SARS-CoV-2 antigen test strips.

Net loss for 2021 was $100.8 million, while net loss for the quarter was $37.2 million, the company said.

Latest in Financial Results
Graph Financial Results Tablet Social
Illumina releases Q2 results, adjusts 2023 guidance
August 14, 2023
Visit our Molecular Diagnostics Community
Sponsored
Visit our Molecular Diagnostics Community
April 5, 2024
Graph Financial Results Bar Chart Social
NeoGenomics Q2 earnings up 18% over 2022 second quarter
August 10, 2023
Financials Growth Revenue Business Social
Labcorp targets growth at new unit after fixing non-human primate supply issues
August 7, 2023
Related Stories
2020 03 24 20 53 4672 Dollar Sign Golden 400
Stock
LumiraDx prices $75.3M public offering
2022 04 01 20 32 7374 Gavel Money 400
Stock
LumiraDx announces proposed share offering
2021 09 27 23 55 5067 Diabetes Insulin Glucose Blood 400
CE mark
LumiraDx diabetes test receives CE Mark
Visit our Molecular Diagnostics Community
Sponsor Content
Visit our Molecular Diagnostics Community
More in Financial Results
Illumina releases Q2 results, adjusts 2023 guidance
By LabPulse.com staff writers
Illumina is lowering its 2023 guidance for total revenue and EPS. The firm now anticipates consolidated revenue growth of approximately 1% year over year, with core Illumina revenues flat for the period.
August 14, 2023
Graph Financial Results Tablet Social
Exact Sciences raises full-year guidance due to demand for colorectal cancer test
By Nick Paul Taylor
Revenues for Exact Sciences’ screening business, which sells the Cologuard colorectal cancer stool test, increased by 31% to $462.8 million in the second quarter.
August 10, 2023
Colon Intestine Social
NeoGenomics Q2 earnings up 18% over 2022 second quarter
By LabPulse.com staff writers
In a call with investors, NeoGenomics CEO Chris Smith attributed the firm’s steady growth to its strategic priorities and improvements in execution.
August 10, 2023
Graph Financial Results Bar Chart Social
Labcorp targets growth at new unit after fixing non-human primate supply issues
By Nick Paul Taylor
While the supply disruption continued to hold back growth in the second quarter, Labcorp told investors it has resolved the problem and there will be no further impact over the second half of the year.
August 7, 2023
Financials Growth Revenue Business Social
Roche’s diagnostic base business growth unable to offset falling COVID-19 sales in Q2
By Nick Paul Taylor
Demand for tests remained high in the first half of last year with the Omicron variant but has since fallen, taking Roche’s revenues down with it. In the first quarter, Roche’s diagnostics sales fell 28% despite 4% growth in the base business.
August 3, 2023
Graph Financial Results Bar Chart Social
Agilent Technologies fiscal Q2 revenues rise 7%; firm trims full-year estimates
By Leo O'Connor
Diagnostics and Genomics Group revenues were $362 million, up 1% year-over-year compared to $358 million.
May 24, 2023
Dna Genome Gene Targeted Social
LumiraDx Q1 revenues drop 82% as its transition from non-COVID tests takes shape
By LabPulse.com staff writers
In April, the company had announced a cost restructuring program involving a reduction of its global workforce by approximately 40%. It now expects to see the full impact of the restructuring activities during the third quarter.
May 16, 2023
Covid 19 Financial Chart Social
OraSure Technologies Q1 revenues up 129% on COVID-19 rapid immunoassay sales
By Leo O'Connor
Demand for rapid tests is tapering, and OraSure is scaling-down COVID-19 test manufacturing amid staff layoffs.
May 11, 2023
Woman Mask Anxiety Covid Social
Exact Sciences shares rise on 24% Q1 revenue growth, higher 2023 guidance
By Leo O'Connor
The firm is seeing a “dramatic increase in the electronic ordering rate” at health systems, which is helping grow sales, its CEO Kevin Conroy said.
May 10, 2023
Colon Intestine Social
Siemens Healthineers Q2 diagnostics revenues drop 39% on decline in rapid antigen test sales
By Leo O'Connor
The firm is seeing a return to low- to mid-single digital revenue growth as swings in demand from COVID-19 testing to routine testing normalize, Sharon Bracken, its president of diagnostics, said in an interview.
May 10, 2023
Business Intelligence Social
Bio-Rad Laboratories Q1 net sales drop 3%; firm lowers full-year guidance
By LabPulse.com staff writers
Bio-Rad shares were down on Friday, a day after the firm updated its financial outlook for full-year 2023; it anticipates non-GAAP currency-neutral revenue growth of approximately 4.5% compared to its previous estimate of 6% to 7%.
May 5, 2023
Business Financial Results Social
Qiagen Q1 net sales decline 23% on COVID headwinds; non-COVID sales rise
By Leo O'Connor
Non-COVID product group sales rose due to underlying double-digit growth at constant exchange rates in consumables and related revenues.
May 4, 2023
Business Intelligence Social
Page 1 of 12
Next Page